Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Classement en actions #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Prix de l'action
$0.0327
Dernière synchronisation: 2025-06-17
Capitalisation boursière
$4.34M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
IL
Échange Gamida Cell Ltd. (GMDA)

Catégorie

Historique du rendement du dividende pour Gamida Cell Ltd. (GMDA)
Le rendement du dividende (TTM) de Gamida Cell Ltd. (symbole boursier : GMDA) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Gamida Cell Ltd. (GMDA) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.48%
BE